Promising news for the treatment of pancreatic cancer in Greece
Published
A significant scientific development is taking place in the field of oncology, offering new hope to thousands of patients. A new drug, daraxonrasib, is showing impressive results in treating pancreatic cancer, a disease considered particularly difficult to treat.
According to recent clinical data, this specific drug has managed to double the median survival of patients participating in the trials. Experts point out that this is the first substantial progress recorded in the treatment of this specific type of cancer in many years.
This positive development directly affects Greek patients as well, as access to the drug has been secured in our country. The ability to use this new treatment is expected to significantly improve the quality of life and the outlook for patients battling the disease.
Medical authorities emphasize that early diagnosis remains the most critical factor for the success of any therapeutic intervention. The addition of daraxonrasib to the arsenal of Greek oncologists represents a decisive step toward better management of pancreatic cancer in the future.
Sources: Skai.gr
More Greece news
- The electric Renault 5 gains greater range and arrives in Greece with a special Roland-Garros edition
- Greece to contribute €120 million to European fund for high-tech companies
- Decline in technology and artificial intelligence stocks: How exposed are Greek companies?
- Meeting of Fidan and Güler on the cable across three capitals
- Interview Poll: New Democracy First with 29.4%, Ten Parties in Parliament
- Greece-Cyprus Cable: What Hatzidakis Said About France's License
- Conference on Access to Healthcare: Stelios Kymbouropoulos on the Today Press panel
- Georgia Parasxou at the Health Access Greece conference